---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000112"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:17:37.648818+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions sells Baltimore-Camden facility to Bora for $30M

## Summary
- Sale of drug product facility to Bora Pharmaceuticals affiliate for total value of ~$30 million.
- Approximately 350 Emergent employees expected to join Bora as part of the transaction.
- Deal is part of multi-year plan to reduce debt, improve profitability, and streamline manufacturing to Lansing and Winnipeg.
- Closing expected in Q3 2024, subject to customary conditions; Truist Securities and Covington & Burling advised Emergent.

## SEC filing metadata
- accession: 0001367644-24-000112
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000112/0001367644-24-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000112/ebs-20240620.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000112
- JSON: https://secwatch.observer/filing/0001367644-24-000112.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.